What Is “Unmet Medical Need?”

Published Nov 6, 2017
A Multistakeholder Panel Addresses the Challenges in the Lack of a Common Definition   Glasgow, Scotland, UK—6 November 2017—ISPOR, the professional society for health economics and outcomes research (HEOR), held a session this afternoon at its 20th Annual European Congress in Glasgow, Scotland, UK that explored the question, “what is ‘unmet medical need?’” The issue panel, “Unmet Medical Need: Should Stakeholders Align on a Definition?” [IP3], was moderated by Claudine Sapede, PharmD, MSc, F. Hoffmann-La Roche Ltd, Basel, Switzerland. Panelists included Nicola Bedlington, European Patients’ Forum and The Patient Access Partnership PACT, Brussels, Belgium; Neil McAuslane, PhD, Center for Innovation in Regulatory Science, London, UK, and Jo De Cock, MS, INAMI—Institut National de l'Assurance Maladie-Invalidité, Brussels, Belgium. Addressing unmet medical need in drug development is a key criterion for medicine prioritization. It is also one of the requirements a molecule candidate needs to satisfy in order to qualify for an adaptive pathways approach and a number of accelerated regulatory review processes, such as PRIME. A common definition of the term “unmet medical need,” however, does not exist. The interpretation of the term may also vary between various stakeholder groups (e.g., regulators, payers, patients, medicine developers). Additionally, the definitions and interpretations of the term may vary between countries and constituents. This lack of common understanding leads to significant challenges in achieving stakeholder alignment on a medicine’s eligibility for accelerated development and patient access pathways. These issues have also been identified by the World Health Organization and the European Parliament that have called on the European Union Commission to define clearly the concept of unmet medical need and on stakeholders to explore new ways of delivering affordable medicines. The multistakeholder panel examined these issues and presented  various perspectives on how the interpretation of unmet medical need will impact pricing and reimbursement decisions in global health care systems. Additional information on the ISPOR 20th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the congress on social media using the hashtag #ISPORGlasgow.

###

  ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: http://bit.ly/ISPOR-T (@ISPORorg) | YouTube: http://bit.ly/ISPOR-YT | Facebook: http://bit.ly/ISPOR-FB

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×